Keywords: antisoma, starts, ph, iii, nsclc, trial, earns

Antisoma starts Ph III NSCLC trial, earns $25M

Article | 21 April 2008

Print This

Antisoma has started a pivotal Phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer, triggering ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in